ClinicalTrials.gg
Active, not recruitingNCT04358107Updated Mar 12, 2026

Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)

An observational study in Adrenocortical Carcinoma, sponsored by National Cancer Institute (NCI). Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by National Cancer Institute (NCI) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Adrenocortical Carcinoma by National Cancer Institute (NCI) — 5 open to participants now, 8 under way, none of them phase 3. Adrenocortical Carcinoma · National Cancer Institute (NCI).

Started
2020
with 1 other
Observational
3 of 18
none open now
Registered
12th of 18
by date

Among the 18 studies in Adrenocortical Carcinoma by National Cancer Institute (NCI), this one is one of 2 that started in 2020, is one of 3 observational ones, and was the 12th registered.

Adrenocortical Carcinoma

94 studies on the registry are indexed under Adrenocortical Carcinoma; 26 are open to participants now.

Browse Adrenocortical Carcinoma studies →

Open to participants now

5 of the 18 studies in Adrenocortical Carcinoma by National Cancer Institute (NCI) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 21 Adrenocortical Carcinoma studies recruiting now, 15 (71%) set no upper age limit and 2 (10%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Adrenocortical Carcinoma by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

Background:

Adrenocortical carcinoma (ACC) is a rare cancer. It has a poor prognosis. Some people live with ACC for years; others live for just months. The average survival from the time of diagnosis is 14.5 months. Researchers do not know if local directed treatments may work better than systemic ones. They want to learn more about ACC by looking at data from previous studies.

Objective:

To characterize the overall prognosis and treatment responses in people with ACC with various systemic therapies and correlate them with age, sex, race, and disease burden.

Eligibility:

People with ACC enrolled on any of the following studies: 92-C-0268, 93-C-0200, 00-C-0044, 01-C-0129, 04-C-0011, 09-C-0242, 08-C-0176, 10-C-0203, 13-C-0114, and 14-C-0029

Design:

Study researchers will review participants medical records. They will collect the following data:

Medical record numbers

Demographics (such as age, sex, and race)

Treatments (such as surgeries, radiology procedures, and systemic treatments)

Time of disease progression between treatments and genetic/molecular data (if available)

Time of diagnosis/time of death.

All data will be kept in secure network drives or sites.

Participants who opted out of future use of data on their prior studies will be not be included in this study.

Read the detailed description

Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75 - 90% and an average survival from the time of diagnosis of 14.5 months.

The natural history of ACC can vary greatly ranging from an aggressive course with patient survival measured in months to a more indolent course with patients living with the disease for years. The basis for these differing clinical presentations is not known. Therefore, accurate survival predictions in ACC are difficult and tumor classification methods with better clinical prognostic value are needed to help rationally guide the clinical management of patients with ACC. Over the last 20+ years in the CCR we have seen patients with ACC in different stages of their disease receiving various types of therapies from local directed therapies to systemic therapies, however, we have been unable to determine if local therapies may improve survival compared to the approved systemic therapies.

In this study, we plan to characterize the overall prognosis and treatment responses among patients with ACC with various systemic therapies and correlate with age, sex, race and disease burden. Identifiers will be recorded in order to correlate outcomes with therapy.

The study will involve review of patient records and will not use specimens or participant contact. The participants whose records will be reviewed in this protocol were enrolled various ACC studies conducted by CCR. The Principal Investigators of each protocol have been contacted and have given permission to conduct this study and have verified that none of the original protocols or informed consent documents precludes such a review of clinical data. Participants who did not consent to future research will be excluded.

03

Conditions studied

  • Adrenocortical Carcinoma

Keywords

  • Treatment Response
  • Prognosis
  • Rare Tumor
  • Natural History
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

primary clinical

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients enrolled on any of the studies listed below:

    • 92-C-0268, 93-C-0200, 00-C-0044, 01-C-0129, 04-C-001, 09-C-0242, 08-C-0176, 10-C-0203, 13-C-0114, 14-C-0029

Exclusion criteria

EXCLUSION CRITERIA:

-Patients who opted out of future use of data on their prior studies will be excluded from this study.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,000 participants (actual)

Groups and cohorts

  • 1

    Medical records of subjects enrolled on various ACC studies conducted by CCR

06

What researchers measure

Primary outcomes

  1. response to treatment

    prognosis and treatment responses among patients with ACC correlated with age, sex, race and disease burden

    Time frame: ongoing

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2020 (actual). Primary completion is estimated for Dec 2026, 80 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2020
First posted
Apr 22, 2020
StartActual
Apr 20, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04358107
Responsible party
Sponsor
First posted
Apr 22, 2020
Start date
Apr 20, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 12, 2026

Study contacts

Jaydira Del Rivero, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion